메뉴 건너뛰기




Volumn 88, Issue 6, 2003, Pages 601-605

Erythropoietin therapy: Need for rationality and active surveillance

Author keywords

[No Author keywords available]

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

EID: 0037774576     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial
Times cited : (10)

References (38)
  • 1
    • 0033568576 scopus 로고    scopus 로고
    • Regulation of the erythropoietin gene
    • Ebert BL, Bunn HF. Regulation of the erythropoietin gene. Blood 1999;94:1864-77.
    • (1999) Blood , vol.94 , pp. 1864-1877
    • Ebert, B.L.1    Bunn, H.F.2
  • 2
    • 0035573882 scopus 로고    scopus 로고
    • The pVHL-hlF-1 system. A key mediator of oxygen homeostasis
    • Maxwell PH, Pugh CW, Ratcliffe PJ. The pVHL-hlF-1 system. A key mediator of oxygen homeostasis. Adv Exp Med Biol 2001;502:365-76.
    • (2001) Adv Exp Med Biol , vol.502 , pp. 365-376
    • Maxwell, P.H.1    Pugh, C.W.2    Ratcliffe, P.J.3
  • 3
    • 0025343574 scopus 로고
    • Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells
    • Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 1990;248:378-81.
    • (1990) Science , vol.248 , pp. 378-381
    • Koury, M.J.1    Bondurant, M.C.2
  • 4
    • 0030974613 scopus 로고    scopus 로고
    • Use of recombinant human erythropoietin outside the setting of uremia
    • Cazzola M, Mercuriali F, Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood 1997;89:4248-67.
    • (1997) Blood , vol.89 , pp. 4248-4267
    • Cazzola, M.1    Mercuriali, F.2    Brugnara, C.3
  • 5
    • 0033833865 scopus 로고    scopus 로고
    • Juvenile hemochromatosis associated with b-thalassemia treated by phlebotomy and recombinant human erythropoietin
    • De Gobbi M, Pasquero P, Brunello F, Paccotti P, Mazza U, Camaschella C. Juvenile hemochromatosis associated with b-thalassemia treated by phlebotomy and recombinant human erythropoietin. Haematologica 2000;85:865-7.
    • (2000) Haematologica , vol.85 , pp. 865-867
    • De Gobbi, M.1    Pasquero, P.2    Brunello, F.3    Paccotti, P.4    Mazza, U.5    Camaschella, C.6
  • 6
    • 0024790160 scopus 로고
    • Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial
    • Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989;111: 992-1000.
    • (1989) Ann Intern Med , vol.111 , pp. 992-1000
    • Eschbach, J.W.1    Abdulhadi, M.H.2    Browne, J.K.3    Delano, B.G.4    Downing, M.R.5    Egrie, J.C.6
  • 7
    • 0026672142 scopus 로고
    • Subjective quality of life assessment in hemodialysis patients at different levels of hemoglobin following use of recombinant human erythropoietin
    • McMahon LP, Dawborn JK. Subjective quality of life assessment in hemodialysis patients at different levels of hemoglobin following use of recombinant human erythropoietin. Am J Nephrol 1992;12:162-9.
    • (1992) Am J Nephrol , vol.12 , pp. 162-169
    • McMahon, L.P.1    Dawborn, J.K.2
  • 8
    • 0033928508 scopus 로고    scopus 로고
    • Impact of hematocrit on morbidity and mortality
    • Collins AJ, Ma JZ, Ebben J. Impact of hematocrit on morbidity and mortality. Semin Nephrol 2000;20:345-9.
    • (2000) Semin Nephrol , vol.20 , pp. 345-349
    • Collins, A.J.1    Ma, J.Z.2    Ebben, J.3
  • 9
    • 0028793205 scopus 로고
    • Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: Dose finding and identification of predictors of response
    • Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 1995;86:4446-53.
    • (1995) Blood , vol.86 , pp. 4446-4453
    • Cazzola, M.1    Messinger, D.2    Battistel, V.3    Bron, D.4    Cimino, R.5    Enller-Ziegler, L.6
  • 10
    • 0030012115 scopus 로고    scopus 로고
    • Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma: A randomized multicenter study
    • The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma
    • Osterborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma: a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood 1996;87:2675-82.
    • (1996) Blood , vol.87 , pp. 2675-2682
    • Osterborg, A.1    Boogaerts, M.A.2    Cimino, R.3    Essers, U.4    Holowiecki, J.5    Juliusson, G.6
  • 11
    • 0037093196 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies
    • Osterborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002;20: 2486-94.
    • (2002) J Clin Oncol , vol.20 , pp. 2486-2494
    • Osterborg, A.1    Brandberg, Y.2    Molostova, V.3    Iosava, G.4    Abdulkadyrov, K.5    Hedenus, M.6
  • 12
    • 0037719383 scopus 로고    scopus 로고
    • Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production
    • in press
    • Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003, in press.
    • (2003) Br J Haematol
    • Cazzola, M.1    Beguin, Y.2    Kloczko, J.3    Spicka, I.4    Coiffier, B.5
  • 14
    • 0036854276 scopus 로고    scopus 로고
    • Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients
    • Beguin Y. Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica 2002;87:1209-21.
    • (2002) Haematologica , vol.87 , pp. 1209-1221
    • Beguin, Y.1
  • 15
    • 0033931311 scopus 로고    scopus 로고
    • The clinical utility of epoetin in cancer patients: A matter of perspective
    • Barosi G, Marchetti M. The clinical utility of epoetin in cancer patients: a matter of perspective. Haematologica 2000;85: 449-50.
    • (2000) Haematologica , vol.85 , pp. 449-450
    • Barosi, G.1    Marchetti, M.2
  • 16
    • 0037075272 scopus 로고    scopus 로고
    • Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin
    • Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-75.
    • (2002) N Engl J Med , vol.346 , pp. 469-475
    • Casadevall, N.1    Nataf, J.2    Viron, B.3    Kolta, A.4    Kiladjian, J.J.5    Martin-Dupont, P.6
  • 18
    • 77952917511 scopus 로고    scopus 로고
    • Johnson & Johnson. Summary of PRCA case reports. Available from URL: http://www.jnj.com/news/jnj_news/1021024_095632.htm
    • Summary of PRCA Case Reports
  • 19
    • 0038752054 scopus 로고    scopus 로고
    • Pure red-cell aplasia due to anti-erythropoietin antibodies
    • Eckardt KU, Casadevall N. Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant 2003;18: 865-9.
    • (2003) Nephrol Dial Transplant , vol.18 , pp. 865-869
    • Eckardt, K.U.1    Casadevall, N.2
  • 21
    • 0037121258 scopus 로고    scopus 로고
    • Benefits of recombinant human erythropoietin
    • Cavill I, Williams JD. Benefits of recombinant human erythropoietin. Lancet 2002;360:1606-7.
    • (2002) Lancet , vol.360 , pp. 1606-1607
    • Cavill, I.1    Williams, J.D.2
  • 22
    • 4243791494 scopus 로고    scopus 로고
    • Epoantibodies induced arythroblastopenia in MDS: Two cases with eitherr alfa or beta recombinant erythropoietin
    • abstract
    • Giraudier S, Quint L, Nataf J, Mayeux P, Casadevall N. Epoantibodies induced arythroblastopenia in MDS: two cases with eitherr alfa or beta recombinant erythropoietin. Leuk Res 2003;27 Suppl 1:S99[abstract].
    • (2003) Leuk Res , vol.27 , Issue.SUPPL. 1
    • Giraudier, S.1    Quint, L.2    Nataf, J.3    Mayeux, P.4    Casadevall, N.5
  • 24
    • 0036433664 scopus 로고    scopus 로고
    • rHuEpo administration in patients with low-risk myelodysplastic syndromes: Evaluation of erythroid precursors' response by fluorescence in situ hybridization on May-Grunwald-Giemsa-stained bone marrow samples
    • Rigolin GM, Porta MD, Bigoni R, Cavazzini F, Ciccone M, Bardi A, et al. rHuEpo administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precursors' response by fluorescence in situ hybridization on May-Grunwald-Giemsa-stained bone marrow samples. Br J Haematol 2002;119:652-9.
    • (2002) Br J Haematol , vol.119 , pp. 652-659
    • Rigolin, G.M.1    Porta, M.D.2    Bigoni, R.3    Cavazzini, F.4    Ciccone, M.5    Bardi, A.6
  • 25
    • 0034243037 scopus 로고    scopus 로고
    • Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome
    • Cazzola M. Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome. Int J Hematol 2000;72:134-8.
    • (2000) Int J Hematol , vol.72 , pp. 134-138
    • Cazzola, M.1
  • 26
    • 0037353935 scopus 로고    scopus 로고
    • A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: Significant effects on quality of life
    • Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003;120:1037-46.
    • (2003) Br J Haematol , vol.120 , pp. 1037-1046
    • Hellstrom-Lindberg, E.1    Gulbrandsen, N.2    Lindberg, G.3    Ahlgren, T.4    Dahl, I.M.5    Dybedal, I.6
  • 27
    • 0036270084 scopus 로고    scopus 로고
    • Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes
    • Wallvik J, Stenke L, Bernell P, Nordahl G, Hippe E, Hast R. Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes. Eur J Haematol 2002;68: 180-5.
    • (2002) Eur J Haematol , vol.68 , pp. 180-185
    • Wallvik, J.1    Stenke, L.2    Bernell, P.3    Nordahl, G.4    Hippe, E.5    Hast, R.6
  • 28
    • 12244277678 scopus 로고    scopus 로고
    • Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology
    • Alessandrino EP, Amadori S, Barosi G, Cazzola M, Grossi A, Liberato LN, et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 2002;87:1286-306.
    • (2002) Haematologica , vol.87 , pp. 1286-1306
    • Alessandrino, E.P.1    Amadori, S.2    Barosi, G.3    Cazzola, M.4    Grossi, A.5    Liberato, L.N.6
  • 29
    • 0036902994 scopus 로고    scopus 로고
    • Practice guidelines for the therapy of primary myelodysplastic syndromes: A word of caution about their translation into clinical practice
    • Cazzola M. Practice guidelines for the therapy of primary myelodysplastic syndromes: a word of caution about their translation into clinical practice. Haematologica 2002;87: 1240-1.
    • (2002) Haematologica , vol.87 , pp. 1240-1241
    • Cazzola, M.1
  • 30
    • 0033624047 scopus 로고    scopus 로고
    • A novel method utilizing markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes
    • Parisotto R, Gore CJ, Emslie KR, Ashenden MJ, Brugnara C, Howe C, et al. A novel method utilizing markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes. Haematologica 2000;85:564-72.
    • (2000) Haematologica , vol.85 , pp. 564-572
    • Parisotto, R.1    Gore, C.J.2    Emslie, K.R.3    Ashenden, M.J.4    Brugnara, C.5    Howe, C.6
  • 31
    • 0033949101 scopus 로고    scopus 로고
    • A global strategy for prevention and detection of blood doping with erythropoietin and related drugs
    • Cazzola M. A global strategy for prevention and detection of blood doping with erythropoietin and related drugs. Haematologica 2000;85:561-3.
    • (2000) Haematologica , vol.85 , pp. 561-563
    • Cazzola, M.1
  • 32
    • 0035103621 scopus 로고    scopus 로고
    • Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erythropoiesis
    • Parisotto R, Wu M, Ashenden MJ, Emslie KR, Gore CJ, Howe C, et al. Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erythropoiesis. Haematologica 2001;86:128-37.
    • (2001) Haematologica , vol.86 , pp. 128-137
    • Parisotto, R.1    Wu, M.2    Ashenden, M.J.3    Emslie, K.R.4    Gore, C.J.5    Howe, C.6
  • 33
    • 0036200569 scopus 로고    scopus 로고
    • A strategy to deter blood doping in sport
    • Ashenden MJ. A strategy to deter blood doping in sport. Haematologica 2002;87:225-32.
    • (2002) Haematologica , vol.87 , pp. 225-232
    • Ashenden, M.J.1
  • 34
    • 0035986784 scopus 로고    scopus 로고
    • Detection of homologous blood transfusion by flow cytometry: A deterrent against blood doping
    • Nelson M, Ashenden M, Langshaw M, Popp H. Detection of homologous blood transfusion by flow cytometry: a deterrent against blood doping. Haematologica 2002;87:881-2.
    • (2002) Haematologica , vol.87 , pp. 881-882
    • Nelson, M.1    Ashenden, M.2    Langshaw, M.3    Popp, H.4
  • 35
    • 0036197438 scopus 로고    scopus 로고
    • Further concerns about the medical risks of blood doping
    • Cazzola M. Further concerns about the medical risks of blood doping. Haematologica 2002;87:232.
    • (2002) Haematologica , vol.87 , pp. 232
    • Cazzola, M.1
  • 36
    • 0035370037 scopus 로고    scopus 로고
    • The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: A randomized controlled study
    • Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001;37:1775-80.
    • (2001) J Am Coll Cardiol , vol.37 , pp. 1775-1780
    • Silverberg, D.S.1    Wexler, D.2    Sheps, D.3    Blum, M.4    Keren, G.5    Baruch, R.6
  • 37
    • 12244284657 scopus 로고    scopus 로고
    • The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron
    • Silverberg DS, Wexler D, Blum M, Tchebiner JZ, Sheps D, Keren G, et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003;18:141-6.
    • (2003) Nephrol Dial Transplant , vol.18 , pp. 141-146
    • Silverberg, D.S.1    Wexler, D.2    Blum, M.3    Tchebiner, J.Z.4    Sheps, D.5    Keren, G.6
  • 38
    • 0038125953 scopus 로고    scopus 로고
    • Once weekly recombinant human erythropoietin therapy is very efficient after allogeneic peripheral blood stem cell transplantation when started soon after engrafment
    • Baron F, Frere P, Beguin Y. Once weekly recombinant human erythropoietin therapy is very efficient after allogeneic peripheral blood stem cell transplantation when started soon after engrafment. Haematologica 2003;88:718-20.
    • (2003) Haematologica , vol.88 , pp. 718-720
    • Baron, F.1    Frere, P.2    Beguin, Y.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.